Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCLEPIOS: Autologous Stem Cells for Hip OA
NCT03608579Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2018
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in osteoarthritis (OA) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Nature, incidence and severity of adverse events at 2 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03608579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608579.